Retraction Retraction dated 2023-09-16
Click to view Retraction: https://doi.org/10.1007/s00280-023-04587-8
-
Authors
Oya, Mototsugu
Kaneko, Shuichi
Imai, Tsuneo
Tsujino, Toshiaki
Sunaya, Toshiyuki
Okayama, Yutaka https://orcid.org/0000-0001-5242-1710
-
Funding
Funding for this research was provided by:
Pfizer (honoraria)
Novartis (honoraria)
Bayer (honoraria)
Bayer (honoraria)
Ono (honoraria)
Ono (honoraria)
BMS (honoraria)
Takeda (honoraria)
Takeda (honoraria)
MSD (honoraria)
MSD (honoraria)
Eisai (honoraria)
Lilly (honoraria)
- License Information
-
More Information
Article History
Received: 22 October 2021
Accepted: 25 March 2022
First Online: 20 April 2022
Change Date: 16 September 2023
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1007/s00280-023-04587-8
Declarations
:
: Dr. Oya has received honoraria from Pfizer, Novartis, Bayer, Ono, BMS, Takeda, and MSD. Dr. Kaneko has received honoraria from Eisai, Bayer, Lilly, Takeda, MSD, and Ono. Dr. Imai declared no competing interests. Toshiaki Tsujino, Toshiyuki Sunaya and Yutaka Okayama are employees of Bayer.
: The authors deeply appreciate the cooperation/contribution of all people who were involved in this survey, including a large number of patients (and their families) with RCC (3335), HCC (1619) or DTC (427). The authors also thank members of the advisory board for the proper use of Nexavar for reviewing our propensity score-matched data. This study was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
